ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

J.P. Kastelein, John; N. Ginsberg, Henry; Langslet, Gisle; Kees Hovingh, G.; Češka, R; Dufour, Robert; Blom, Dirk; Civeira, Fernando; Krempf, Michel; Lorenzato, Christelle; Zhao, Jian; Pordy, Robert; T. Baccara‐Dinet, Marie; A. Gipe, Daniel; Jane Geiger, Mary; Farnier, Michel

doi:10.1093/eurheartj/ehv370

Public

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

Published in European Heart Journal • Sep 1, 2015

Authors:

John J.P. Kastelein

Henry N. Ginsberg

Gisle Langslet

Abstract

AIMS: To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous familial hypercholesterolaemia (HeFH) and inadequate LDL-C control on maximally tolerated lipid-lowering therapy (LLT). METHODS AND RESULTS: In two randomized, double-blind studies (ODYSSEY FH I, n = 486; FH II, ...

Subject

Alirocumab

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!